MK-8189

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Schizophrenia

Phase 1

A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)

CompletedNCT03565068

Merck Sharp & Dohme LLCSchizophrenia

Start: 2018-06-20End: 2020-04-03Updated: 2021-03-29

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

CompletedNCT05953740

Merck Sharp & Dohme LLCSchizophrenia

Start: 2023-09-15End: 2024-02-15Updated: 2025-03-04